163 related articles for article (PubMed ID: 21421119)
1. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum.
Sajid S; Mohile SG; Szmulewitz R; Posadas E; Dale W
Semin Oncol; 2011 Apr; 38(2):309-25. PubMed ID: 21421119
[TBL] [Abstract][Full Text] [Related]
2. Management of prostate cancer in the older man.
Mohile SG; Lachs M; Dale W
Semin Oncol; 2008 Dec; 35(6):597-617. PubMed ID: 19027464
[TBL] [Abstract][Full Text] [Related]
3. Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.
Hoffman KE
Semin Radiat Oncol; 2012 Oct; 22(4):284-94. PubMed ID: 22985811
[TBL] [Abstract][Full Text] [Related]
4. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer in the elderly patient.
Fung C; Dale W; Mohile SG
J Clin Oncol; 2014 Aug; 32(24):2523-30. PubMed ID: 25071137
[TBL] [Abstract][Full Text] [Related]
6. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer in the elderly.
Heinzer H; Steuber T
Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477
[TBL] [Abstract][Full Text] [Related]
9. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.
D'Amico AV; Braccioforte MH; Moran BJ; Chen MH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1329-37. PubMed ID: 19879061
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
Mohile SG; Bylow K; Dale W; Dignam J; Martin K; Petrylak DP; Stadler WM; Rodin M
Cancer; 2007 Feb; 109(4):802-10. PubMed ID: 17219443
[TBL] [Abstract][Full Text] [Related]
11. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
12. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
14. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
15. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
[TBL] [Abstract][Full Text] [Related]
16. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
[TBL] [Abstract][Full Text] [Related]
17. Results of conservative management of clinically localized prostate cancer.
Chodak GW; Thisted RA; Gerber GS; Johansson JE; Adolfsson J; Jones GW; Chisholm GD; Moskovitz B; Livne PM; Warner J
N Engl J Med; 1994 Jan; 330(4):242-8. PubMed ID: 8272085
[TBL] [Abstract][Full Text] [Related]
18. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
19. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
[TBL] [Abstract][Full Text] [Related]
20. Men considering a hypothetical treatment for prostate cancer: a comparison to patients.
Van Manen L; Feldman-Stewart D; Brundage MD
Patient Educ Couns; 2006 Apr; 61(1):33-42. PubMed ID: 16257170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
